PROGRAM CHAIR
Mario Castro, MD, MPH
L.E Phillips and Lenora Carr Phillips Professor
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers Institute for Clinical and Translational Science at the University of Kansas
University of Kansas School of Medicine
Kansas City, KS
PROGRAM OVERVIEW
This enduring TeleECHO educational series focuses on up-to-date understanding of the latest data in the management of moderate-to-severe asthma while reviewing the risks associated with the use of oral corticosteroids (OCS) in this setting. Case-based learning through patient presentations combined with clinical questions will provide expert discussion that will apply data for both approved and investigational biologics and highlight the risks of OCS while providing alternatives to their use in moderate-to-severe disease.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community primary care clinicians, allergists, immunologists, pulmonologists, otolaryngologists (ENT specialists), and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of moderate-to-severe asthma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the burden chronic OCS usage imparts on achieving treatment goals, daily QoL, and associated toxicities in managing asthma
- Discuss the clinical evidence for approved and investigational biologics for the treatment of moderate-to-severe asthma
- Detail strategies to improve appropriate referrals to implement multidisciplinary care effectively
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Mario Castro, MD | Discloses that he has received consulting fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead Pharmaceuticals, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines and GlaxoSmithKline. He has served on the Speakers’ Bureau for Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis and Teva. Dr. Castro has conducted Contracted Research for AstraZeneca, Gala Therapeutics, GlaxoSmithKline, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi and Theravance Biopharma. In addition, he has stock options from Aer Therapeutics. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dominque Barton, RN, has nothing to disclose.
- Michael Milano, MD discloses that he has received royalties from Wolters Kluwer.
- Dave Chatman, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
RELEASED DATE: May 17, 2024
EXPIRATION DATE: May 17, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
